|
|
New & Noteworthy
Full FDA Approval of the Jarvik 2000® Destination Therapy Trial
Device to Provide Long-term, Permanent Support for Heart Failure Patients Who are Not Eligible for Transplant. Approval was also granted for Continuing Access Protocol (CAP) Patients Following Completion of Enrollment in the Bridge to Transplant Trial. [Read More] |
|
Learn more about the behind-the-ear cable design of the Jarvik 2000 model to be used in the DT study. The study is designed to determine if this design is superior to LVADs that use an abdominal cable and have an abdominal pump pocket.
|
|
Who We Are
Jarvik Heart is a leading developer of miniaturized heart assist devices for the treatment of severe congestive heart failure. The Jarvik 2000 FlowMaker® mechanical heart, the company's silent titanium axial-flow blood pump, has successfully sustained and improved the condition of heart failure patients awaiting heart transplants, as well as those who have chosen the device for lifetime-use.
|
|
